chartexchange

IBRX270319C00011000
IBRX Mar 19 2027 11.00 Call
optionOPRA

EODOct 16, 2026
1.60USD-41.818%(-1.15)11Vol921OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
11
Expiration
Mar 19, 2027
DTE
150d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.05-80.00%541,377
Oct 30, 202610d$0.25-28.57%232,025
Nov 6, 202617d$0.45-18.18%34379
Nov 13, 202624d$0.80-20.00%9437
Nov 20, 202631d$0.55-37.50%6305,863
Nov 27, 202638d$1.02+27.50%66
Dec 18, 202659d$1.35+0.00%3621
Jan 15, 202787d$1.15-32.35%39216,123
Mar 19, 2027150d$1.60-41.82%11921
Apr 16, 2027178d$2.48-0.80%198
May 21, 2027213d$3.00-3.23%1420
IBRX Nearby Strikes · Mar 19, 2027
StrikeLastChangeVolOpen IntMoneyness
5 C$5.40+0.93%15350ITM
6 C$4.45-3.26%217ITM
7 C$4.03-4.05%1255ITM
8 C$3.00-11.76%591,300ITM
9 C$2.30-24.09%73428OTM
10 C$2.20-21.43%1921,298OTM
11 C$1.60-41.82%11921OTM
12 C$1.40-31.71%3385OTM
13 C$2.00+42.86%523OTM
14 C$1.50-25.74%530OTM
15 C$0.95-40.63%22,008OTM
16 C$1.66-12.63%655OTM
17 C$0.70-29.29%2551OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.